

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:**IN THE CLAIMS**

Please amend the claims as follows, without prejudice to refile:

Claims 1-8. (canceled)

9. (previously presented) A protein, which protein (a) competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, (b) increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%, and (c) comprises a human immunoglobulin constant domain.

Claims 10-20. (canceled)

21. (currently amended) A pharmaceutical composition comprising:
- (a) a molecule comprising SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10, which molecule (i) binds CD40, (ii) increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%, and (iii) comprises a human immunoglobulin constant domain, in an amount effective for the treatment or ~~prevention~~ of cancer; and
 - (b) a pharmaceutically acceptable carrier.
22. (currently amended) A pharmaceutical composition comprising:
- (a) a protein, which protein (i) competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, (ii) increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%, and (iii) comprises a human immunoglobulin constant domain, in an amount effective for the treatment or ~~prevention~~ of cancer; and
 - (b) a pharmaceutically acceptable carrier.

23. (previously presented) A pharmaceutical composition comprising:
- (a) a molecule comprising SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10, which molecule (i) binds CD40, (ii) increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%, and (iii) comprises a human immunoglobulin constant domain, in an amount effective for activating or augmenting an immune response; and
 - (b) a pharmaceutically acceptable carrier.
24. (previously presented) A pharmaceutical composition comprising:
- (a) a protein, which protein (i) competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, (ii) increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%, and (iii) comprises a human immunoglobulin constant domain, in an amount effective for activating or augmenting an immune response; and
 - (b) a pharmaceutically acceptable carrier.
25. (original) The pharmaceutical composition of any one of claims 21-24 further comprising CD40 ligand.

Claims 26-34 (canceled)

Claim 35. (withdrawn) A transgenic non-human animal, plant, or an isolated cell containing one or more transgenes encoding a protein, which protein competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-220, and which protein increases the binding of CD40 ligand to CD40 by at least 45%.

36. (currently amended) A pharmaceutical composition comprising in an amount effective for the treatment ~~or prevention of cancer or an immune disorder~~, or for activating or augmenting an immune response: (a) ~~a molecule~~ an antibody that binds CD40, which ~~molecule~~ antibody increases the binding of CD40 ligand to cell surface

CD40 on B cells by at least 45%; (b) CD40 ligand; and (c) a pharmaceutically acceptable carrier.

Claims 37-51. (canceled)

52. (currently amended) The protein of claim ~~8~~ 9, which increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 50%.

53. (currently amended) The protein of claim ~~8~~ 9, which increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 60%.

54. (currently amended) The protein of claim ~~8~~ 9, which increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 65%.

Claim 55. (canceled)

56. (currently amended) The protein of claim ~~8~~ 9, which is a fragment of an antibody containing the binding domain of the antibody.

57. (currently amended) The protein of claim ~~8, 9, or 44~~ which is purified.

Claims 58-59. (canceled)

60. (original) The protein of claim 56 which is purified.

61. (currently amended) The pharmaceutical composition of claim 21, or 23 ~~or 36~~, in which the molecule is purified.

Claims 62-65. (canceled)

66. (original) The pharmaceutical composition of claim 22 or 24, in which the protein is purified.

67. (original) The pharmaceutical composition of claim 25, in which the CD40 ligand is purified.

Claim 68. (canceled)

69. (currently amended) ~~A molecule~~ An antibody that (a) binds to CD40; (b) increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%; and (c) comprises a human immunoglobulin constant domain.

Claims 70-71. (canceled)

72. (currently amended) The ~~molecule~~ antibody of any one of claim ~~claims~~ ~~1-3~~ and 69 which is conjugated to a chemotherapeutic agent.

73. (currently amended) The ~~protein~~ antibody of any one of claim ~~claims~~ ~~8, 9~~ and ~~44~~ which is conjugated to a chemotherapeutic agent.

Claims 74-76. (canceled)

77. (previously presented) The pharmaceutical composition of claim 21 or 23 in which the molecule is conjugated to a chemotherapeutic agent.

78. (previously presented) The pharmaceutical composition of claim 22 or 24 in which the protein is conjugated to a chemotherapeutic agent.

Claims 79-91. (canceled)